• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Consumer Cyclical·6578.TWO
Share

DaBomb Protein Biotech Corp. Stocks

NT$ 16.2Last Updated 28.07.2026

Issuer Rating

2/7
Performance

Poor

Risk

Considerable

Recommendation

Sell

Market Cap

NT$ 35.84M

NT$ 16.2
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

DaBomb Protein Biotech Corp. is a specialized biotechnology enterprise primarily dedicated to developing and commercializing antibiotic replacements for the animal health industry. Its extensive product range includes plant-based proteins such as DaBomb-P (Aqua) and DaBomb-P (Livestock), alongside specific antibiotic alternative solutions like DBT-100 HT and DBT-100 LS. The company also manufactures pet care products, featuring LACTOTIDES HEALTH A+ and Liqui-TIDE bandages. Founded in 2001 and headquartered in Tainan, Taiwan, the firm adopted its current name, DaBomb Protein Biotech Corp., in October 2023, having previously operated as DaBomb Protein Corp.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is 'expensive' on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.07.2026 13:47

An Nvidia employee was detained in Taiwan in connection with a case involving the smuggling of AI chips to China

28.07.2026 12:29

Samsung and SK Hynix Plummeted Ahead of Earnings Reports: News from China Fueled Investor Fears

28.07.2026 12:00

Is Cartier the New Birkin? Investors Are Looking for the Next Big Thing in the World of Luxury

28.07.2026 10:42

Top Stories This Morning: New U.S. Rules for AI, a Plunge in Chipmakers’ Stocks and the South Korean Stock Market

28.07.2026 09:00

Rivian is benefiting from the growth of robotaxis. One analyst expects the stock to rise 26%.

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026